Metrics as of 10/17/2026, 08:31 AM (Berlin time), refresh in progress.
Stoke Therapeutics Stock
Stoke Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Ian F. Smith
- Employees
- 170
- Market cap
- $1.6 B
- IPO
- 19/06/2019
Stoke Therapeutics, Inc. is an emerging biopharmaceutical company in the healthcare sector dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Headquartered in Bedford, USA, the company was founded in 2014. Its primary focus involves targeting and addressing the fundamental causes of severe…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Stoke Therapeutics stock: price history
1D
-1.8%
1W
-2.3%
1M
-13.4%
6M
-35.1%
YTD
-23.9%
1Y
-29.3%
2Y
+85.5%
5Y
+2.8%
10Y
–
Next earnings date
Next earnings date
03/11/2026 (in 17 days)
Volatility around earnings
~56% stronger price swings than usual
Ask the agents about Stoke Therapeutics
Analyst assessment of Stoke Therapeutics
PRICE TARGET LOW
US$44.00
CONSENSUS
US$51.00
MEDIAN
US$51.00
PRICE TARGET HIGH
US$58.00
0
STRONG BUY
13
BUY
3
HOLD
0
SELL
0
STRONG SELL
16
TOTAL · Buy
As of: 04/08/2026
Stoke Therapeutics stock metrics
P/E
-7.19
P/B
4.62
EV/EBITDA
-7.01
RETURN ON EQUITY
-17.8%
NET MARGIN
-660.8%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
70.7%
FLOAT SHARES
45,614,246
AVG. DAILY VOLUME (30D)
913,504
Insider transactions (SEC)
Allan Jonathan
Ticho Barry
Ticho Barry
Ticho Barry
Ticho Barry
Institutional holders
Comparable stocks
Frequently asked questions about Stoke Therapeutics stock
What does Stoke Therapeutics do?
Stoke Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Ian F. Smith, the company employs around 170 people.
The IPO was on 19/06/2019; the stock trades on NASDAQ under the ticker STOK.
What do analysts say about Stoke Therapeutics stock?
16 analysts rate the stock, the consensus is Buy (as of 04/08/2026).
The average price target is US$51.00, ranging from US$44.00 to US$58.00, with a median of US$51.00.
This is an external assessment, not a statement by Market Jury.
When does Stoke Therapeutics report next?
The next earnings date is 03/11/2026.
Around past earnings, price swings were roughly 56% stronger than usual.
Does Stoke Therapeutics pay a dividend?
No, Stoke Therapeutics currently does not pay a dividend.
Which stocks are comparable to Stoke Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Stoke Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Stoke Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.